TRIM Proteins in Colorectal Cancer: TRIM8 as a Promising Therapeutic Target in Chemo Resistance
Open Access
- 27 February 2021
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 9 (3) , 241
Abstract
Colorectal cancer (CRC) represents one of the most widespread forms of cancer in the population and, as all malignant tumors, often develops resistance to chemotherapies with consequent tumor growth and spreading leading to the patient’s premature death. For this reason, a great challenge is to identify new therapeutic targets, able to restore the drugs sensitivity of cancer cells. In this review, we discuss the role of TRIpartite Motifs (TRIM) proteins in cancers and in CRC chemoresistance, focusing on the tumor-suppressor role of TRIM8 protein in the reactivation of the CRC cells sensitivity to drugs currently used in the clinical practice. Since the restoration of TRIM8 protein levels in CRC cells recovers chemotherapy response, it may represent a new promising therapeutic target in the treatment of CRC.Keywords
This publication has 263 references indexed in Scilit:
- Wnt/β-Catenin Signaling and DiseaseCell, 2012
- TRIM24 links a non-canonical histone signature to breast cancerNature, 2010
- IKK/NF‐κB and STAT3 pathways: central signalling hubs in inflammation‐mediated tumour promotion and metastasisEMBO Reports, 2009
- Inflammation and Cancer: IL-6 and STAT3 Complete the LinkCancer Cell, 2009
- Non-Smad pathways in TGF-β signalingCell Research, 2008
- Shared Principles in NF-κB SignalingCell, 2008
- Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levelsBritish Journal of Cancer, 2007
- Cellular processing of platinum anticancer drugsNature Reviews Drug Discovery, 2005
- Recognition and processing of cisplatin- and oxaliplatin-DNA adductsCritical Reviews in Oncology/Hematology, 2005
- Smad-dependent and Smad-independent pathways in TGF-β family signallingNature, 2003